A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Condition: Hepatitis B, ChronicIntervention: Drug: Peginterferon alfa-2aSponsor: Hoffmann-La RocheAvailable - verified June 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2016 Category: Research Source Type: clinical trials
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
Condition: Hepatitis C, ChronicInterventions: Drug: Ribavirin; Drug: peginterferon alfa-2aSponsor: Hoffmann-La RocheTerminated - verified June 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2016 Category: Research Source Type: clinical trials
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Condition: Hepatitis B, ChronicIntervention: Drug: Peginterferon alfa-2aSponsor: Hoffmann-La RocheAvailable - verified June 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2016 Category: Research Source Type: clinical trials
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
Condition: Hepatitis C, ChronicInterventions: Drug: Ribavirin; Drug: peginterferon alfa-2aSponsor: Hoffmann-La RocheTerminated - verified June 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2016 Category: Research Source Type: clinical trials
Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)
Condition: HIV/HCV CoinfectionIntervention: Drug: Peginterferon Alfa-2Sponsor: Hoffmann-La RocheTerminated - verified May 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 3, 2016 Category: Research Source Type: clinical trials
